Advances in basic research, clinical diagnosis and treatment of thyroid cancer in 2022

doi:10.19401/j.cnki.1007-3639.2023.05.001

Abstract

Abstract:

Thyroid cancer is a common malignancy of the endocrine system with a significantly increased incidence in recent years. Surgical treatment is the primary treatment, followed by endocrine therapy and radionuclide therapy according to the clinical evaluations, and in some cases, radiotherapy and targeted therapy are needed. However, the mortality of thyroid cancer also tends to increase, especially in advanced or low/dedifferentiated patients with poor prognosis and short survival time. With the advancement of basic and clinical research, new progress has been made in individualized treatment of thyroid cancer. This article reviewed the research progress of thyroid cancer in 2022.

Key words: Thyroid cancer, Epidemiology, Basic research, Clinical research, Progress

CLC Number:

R736.1

QU Ning, WANG Yuting, MA Ben, WANG Yu. Advances in basic research, clinical diagnosis and treatment of thyroid cancer in 2022[J]. China Oncology, 2023, 33(5): 423-430.

References 40

[1]	ZHENG R, ZHANG S, ZENG H, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Center, 2022, 2(1):1-9 doi: 10.1016/j.jncc.2022.02.002
[2]	ZHOU M G, WANG H D, ZENG X Y, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. doi: S0140-6736(19)30427-1 pmid: 31248666
[3]	张新洲, 刘劲松, 许娴, 等. 2005—2016年中国甲状腺癌发病和死亡趋势分析[J]. 中华肿瘤防治杂志, 2022, 29(24): 1725-1733.
	ZHANG X Z, LIU J S, XU X, et al. Trends of thyroid cancer incidence and mortality in China from 2005 to 2016[J]. Chin J Cancer Prev Treat, 2022, 29(24): 1725-1733.
[4]	CHEN W Q, ZHENG R S, ZUO T T, et al. National cancer incidence and mortality in China, 2012[J]. Chin J Cancer Res, 2016, 28(1): 1-11.
[5]	HONGMEI, ZENG, PHD, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555-e567.
[6]	VACCARELLA S, LORTET-TIEULENT J, COLOMBET M, et al. Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: a population-based study[J]. Lancet Diabetes Endocrinol, 2021, 9(3): 144-152. doi: 10.1016/S2213-8587(20)30401-0
[7]	黄志刚, 陈晓红. 分化型甲状腺癌个体化分层治疗的策略和意义[J]. 中华耳鼻咽喉头颈外科杂志, 2017, 52 (6): 405-409
	HUANG Z G, CHEN X H. The strategy and significance of individualized stratified therapy for differentiated thyroid carcinoma[J]. Chin J Otorhinolaryngol Head Neck Surg, 2017, 52(6): 405-409.
[8]	ROMEI C, CIAMPI R, ELISEI R. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma[J]. Nat Rev Endocrinol, 2016, 12(4): 192-202. doi: 10.1038/nrendo.2016.11 pmid: 26868437
[9]	贺青卿, 于芳, 范子义, 等. 单中心2 038例甲状腺癌20年随访及危险因素分析[J]. 中华内分泌外科杂志, 2022, 16(1): 18-22.
	HE Q Q, YU F, FAN Z Y, et al. Risk factor analysis of 20-year follow-up of 2 038 cases of thyroid cancer: a single center study[J]. Chin J Endocr Surg, 2022, 16(1): 18-22.
[10]	LI X C, ZHANG S, ZHANG Q, et al. Diagnosis of thyroid cancer using deep convolutional neural network models applied to sonographic images: a retrospective, multicohort, diagnostic study[J]. Lancet Oncol, 2019, 20(2): 193-201. doi: S1470-2045(18)30762-9 pmid: 30583848
[11]	FRANCO A T, RICARTE-FILHO J C, ISAZA A, et al. Fusion oncogenes are associated with increased metastatic capacity and persistent disease in pediatric thyroid cancers[J]. J Clin Oncol, 2022, 40(10): 1081-1090. doi: 10.1200/JCO.21.01861 pmid: 35015563
[12]	DOOLITTLE W K L, ZHAO L, CHENG S Y. Blocking CDK7-mediated NOTCH1-cMYC signaling attenuates cancer stem cell activity in anaplastic thyroid cancer[J]. Thyroid, 2022, 32(8): 937-948. doi: 10.1089/thy.2022.0087 pmid: 35822558
[13]	ZHANG P T, GUAN H X, YUAN S K, et al. Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors[J]. Nat Commun, 2022, 13(1): 1588. doi: 10.1038/s41467-022-29000-5
[14]	孙海燕, 弓磊, 于振涛, 等. 髓源性抑制细胞联合免疫检查点抑制剂抗肿瘤治疗的研究进展[J]. 肿瘤防治研究, 2020, 47(9)716-721
	SUN H Y, GONG L, YU Z T, et al. Advances in anti-tumor therapy of myeloid-derived suppressor cells combined with immunological checkpoint inhibitors[J]. Cancer Res Prev Treat, 2020, 47(9)716-721
[15]	RABOLD K, ZOODSMA M, GRONDMAN I, et al. Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma[J]. Nat Commun, 2022, 13(1): 6149. doi: 10.1038/s41467-022-33907-4 pmid: 36257966
[16]	YIP L, SOSA J A. Molecular-directed treatment of differentiated thyroid cancer: advances in diagnosis and treatment[J]. JAMA Surg, 2016, 151(7): 663-670. doi: 10.1001/jamasurg.2016.0825 pmid: 27223483
[17]	PENG S, LIU Y H, LV W M, et al. Deep learning-based artificial intelligence model to assist thyroid nodule diagnosis and management: a multicentre diagnostic study[J]. Lancet Digit Health, 2021, 3(4): e250-e259.
[18]	MONTERO-CONDE C, LEANDRO-GARCÍA L J, et al.MARTÍNEZ-MONTES Á M, Comprehensive molecular analysis of immortalization hallmarks in thyroid cancer reveals new prognostic markers[J]. Clin Transl Med, 2022, 12(8): e1001.
[19]	SUN Y T, SELVARAJAN S, ZANG Z L, et al. Artificial intelligence defines protein-based classification of thyroid nodules[J]. Cell Discov, 2022, 8(1): 85. doi: 10.1038/s41421-022-00442-x pmid: 36068205
[20]	SHI X, SUN Y, SHEN C, et al. Integrated proteogenomic characterization of medullary thyroid carcinoma[J]. Cell Discov, 2022, 8(1): 120. doi: 10.1038/s41421-022-00479-y pmid: 36344509
[21]	National Cancer Center, Thyroid Cancer Expert Committee of National Cancer Quality Control Center. Quality control index for standardized diagnosis and treatment of thyroid cancer in China (2022 edition)[J]. Chin J Oncol, 2022, 44(9): 902-907.
[22]	FILETTI S, DURANTE C, HARTL D, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2019, 30(12): 1856-1883. doi: S0923-7534(20)32555-2 pmid: 31987292
[23]	ZHANG Z Y, SUN B T, OUYANG H, et al. Endoscopic lateral neck dissection: a new frontier in endoscopic thyroid surgery[J]. Front Endocrinol (Lausanne), 2021, 12: 796984. doi: 10.3389/fendo.2021.796984
[24]	中国抗癌协会. 中国肿瘤整合诊治指南(CACA)甲状腺癌2022版[M]. 天津科学技术出版社, 2022.
	China Anti-Cancer Association. China Cancer Integrated Diagnosis and Treatment Guidelines (CACA) for thyroid cancer 2022 edition[M]. Tianjin Science and Technology Press, 2022.
[25]	中华人民共和国国家卫生健康委员会医政医管局. 甲状腺癌诊疗指南(2022年版)[J]. 中国实用外科杂志, 2022, 42(12): 1343-1357, 1363.
	National Health Commission of the People’s Republic of China Medical Administration and Hospital Administration. Guidelines for the diagnosis and treatment of thyroid carcinoma[J]. Chin J Pract Surg, 2022, 42(12): 1343-1357, 1363.
[26]	纪玲霞, 周爱琴, 周雪梅. 调强放疗治疗甲状腺癌术后残留和复发的临床效果研究[J]. 实用癌症杂志, 2022, 37(5): 858-860
	JI L X, ZHOU A Q, ZHOU X M. Clinical study on the effect of intensive modulation radiotherapy in the treatment of residue and recurrence after thyroid cancer[J]. Pract J Cancer, 2022, 37(5): 858-860
[27]	KWON J, KIM B H, JUNG H W, et al. The prognostic impacts of postoperative radiotherapy in the patients with resected anaplastic thyroid carcinoma: a systematic review and meta-analysis[J]. Eur J Cancer, 2016, 59: 34-45. doi: S0959-8049(16)00130-1 pmid: 27014798
[28]	ORLANDI F, CARACI P, BERRUTI A, et al. Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer[J]. Ann Oncol, 1994, 5(8): 763-765. pmid: 7826911
[29]	SCHLUMBERGER M, LEBOULLEUX S. Current practice in patients with differentiated thyroid cancer[J]. Nat Rev Endocrinol, 2021, 17(3): 176-188. doi: 10.1038/s41574-020-00448-z pmid: 33339988
[30]	HO A L, DEDECJUS M, WIRTH L J, et al. Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer: a phase Ⅲ, randomized, placebo-controlled trial (ASTRA)[J]. J Clin Oncol, 2022, 40(17): 1870-1878. doi: 10.1200/JCO.21.00714
[31]	CAO J J, ZHU X L, SUN Y R, et al. The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer[J]. Eur J Nucl Med Mol Imaging, 2022, 49(10): 3470-3481. doi: 10.1007/s00259-022-05820-x
[32]	NABHAN F, DEDHIA P H, RINGEL M D. Thyroid cancer, recent advances in diagnosis and therapy[J]. Int J Cancer, 2021, 149(5): 984-992. doi: 10.1002/ijc.33690 pmid: 34013533
[33]	National Comprehensive Cancer Network. NCCN clinical practice guidelines in thyroid cancer (2022 version Ⅰ)[DB/OL]. [2023-04-28]. http://www.nccn.org.
[34]	SUBBIAH V, KREITMAN R J, WAINBERG Z A, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase Ⅱ ROAR basket study[J]. Ann Oncol, 2022, 33(4): 406-415. doi: 10.1016/j.annonc.2021.12.014
[35]	HUANG N S, WEI W J, XIANG J, et al. The efficacy and safety of anlotinib in neoadjuvant treatment of locally advanced thyroid cancer: a single-arm phase Ⅱ clinical trial[J]. Thyroid, 2021, 31(12): 1808-1813. doi: 10.1089/thy.2021.0307
[36]	SARONNI D, GAUDENZI G, DICITORE A, et al. Preclinical evaluation of novel tyrosine-kinase inhibitors in medullary thyroid cancer[J]. Cancers (Basel), 2022, 14(18): 4442. doi: 10.3390/cancers14184442
[37]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021[J]. 肿瘤预防与治疗, 2021, 34(12): 1164-1201.
	Working Committee of the Guidelines of the Chinese Society of Clinical Oncology. Guidelines of Chinese Society of Clinical Oncology (CSCO) differentiated thyroid cancer[J]. J Cancer Control Treat, 2021, 34(12): 1164-1201.
[38]	SUBBIAH V, HU M I, WIRTH L J, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study[J]. Lancet Diabetes Endocrinol, 2021, 9(8): 491-501. doi: 10.1016/S2213-8587(21)00120-0
[39]	RAMAN R, VILLEFRANC J A, ULLMANN T M, et al. Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancer[J]. J Exp Med, 2022, 219(6): e20210390.
[40]	LEE Y A, LEE H, IM S W, et al. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake[J]. J Clin Invest, 2021, 131(18): e144847.
	WAGUESPACK S G, DRILON A, LIN J J, et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma[J]. Eur J Endocrinol, 2022, 186(6): 631-643. doi: 10.1530/EJE-21-1259